◎ Sugi Atlas

Atlas / Disease / Meningeal tuberculosis

Meningeal tuberculosis

disease
On this page

Also known as Meningitis, TuberculousTB meningitisTBMtubercular meningitistuberculous meningitis

Summary

Meningeal tuberculosis (MONDO:0006042) is a disease with 6 GWAS associations across 2 studies and 21 clinical trials. Top therapeutic interventions include dexamethasone, isoniazid, and moxifloxacin. A subtype of tuberculous salpingitis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • GWAS associations: 6
  • Clinical trials: 21

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical namemeningeal tuberculosis
Mondo IDMONDO:0006042
EFOEFO:1000039
MeSHD014390
Orphanet499004
ICD-10-CMA17.0
NCITC84888
SNOMED CT58437007
UMLSC0041318
MedGen21725
GARD0007828
NORD1437
Is cancer (heuristic)no

Also known as: Meningitis, Tuberculous · TB meningitis · TBM · tubercular meningitis · tuberculous meningitis

Data availability: 6 GWAS associations (2 studies).

Disease family

This is a subtype of tuberculous salpingitis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › reproductive system disorder › female reproductive system disorder › pelvic inflammatory disease › salpingitis › tuberculous salpingitis › meningeal tuberculosis

Genetics & variants

GWAS landscape

6 GWAS associations across 2 studies. Top hits map to 4 distinct genes (as reported by GWAS).

Top associations by p-value

rsIDp-valueGeneRisk alleleOdds ratio
rs26793085e-06DYNLRB2-AS1?26.43
rs778574296e-06GBA3?4.28
rs21407796e-06LINC01101 - Y_RNA?18.12
rs43094476e-06MTCO1P40 - RPS2P48?3.7
rs37604959e-06GLOD4?2.72
rs131890211e-05SLC6A3?11.66

Top studies (by case count)

StudyLead authorYearCasesControlsTitle
GCST90104952Schurz H20221140Deciphering Genetic Susceptibility to Tuberculous Meningitis.
GCST90104953Schurz H20221140Deciphering Genetic Susceptibility to Tuberculous Meningitis.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

TierVariants
Tier 1: coding0
Tier 2: splice/UTR0
Tier 3: regulatory0
Tier 4: intronic/intergenic6

MAF distribution

BucketVariants
common (>=0.05)6
low_freq (0.01-0.05)0
rare (<0.01)0
unknown0

Functional consequences

ConsequenceCount
intron_variant4
non_coding_transcript_exon_variant2

Top variants

rsIDChrPosAllelesMAFConsequenceGenep-valueTier
rs26793081680316814G>A,C,T0.05intron_variantDYNLRB2-AS15e-06Tier 4: intronic/intergenic
rs77857429422802462C>T0.05intron_variantGBA36e-06Tier 4: intronic/intergenic
rs21407792120545143C>A,T0.05non_coding_transcript_exon_variantLINC01101 - Y_RNA6e-06Tier 4: intronic/intergenic
rs43094471753561187G>A0.05intron_variantMTCO1P40 - RPS2P486e-06Tier 4: intronic/intergenic
rs376049517781489C>T0.05intron_variantGLOD49e-06Tier 4: intronic/intergenic
rs1318902151442727C>A,T0.05non_coding_transcript_exon_variantSLC6A31e-05Tier 4: intronic/intergenic

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

4 approved. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

DrugDevelopment status
Cortisone AcetateApproved (phase 4)
DexamethasoneApproved (phase 4)
PrednisoloneApproved (phase 4)
PrednisoneApproved (phase 4)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Moxifloxacin.

Clinical trials & evidence

Clinical trials

Clinical trials: 21.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified9
PHASE26
PHASE34
PHASE41
PHASE2/PHASE31

Top trials by phase / activity

NCTPhaseStatusTitle
NCT02588196PHASE4UNKNOWNThe Relationships Between Gene Polymorphisms of LTA4H and Dexamethasone Treatment for Tuberculous Meningitis
NCT05917340PHASE3NOT_YET_RECRUITINGIntensified Short Course Regimen for TBM in Adults
NCT03092817PHASE3COMPLETEDAdjunctive Corticosteroids for Tuberculous Meningitis in HIV-infected Adults (The ACT HIV Trial)
NCT03100786PHASE3COMPLETEDLeukotriene A4 Hydrolase Stratified Trial of Adjunctive Corticosteroids for HIV-uninfected Adults With Tuberculous Meningitis
NCT04145258PHASE3UNKNOWNIntensified Tuberculosis Treatment to Reduce the Mortality of Patients With Tuberculous Meningitis
NCT04620772PHASE2/PHASE3UNKNOWNCyclophosphamide in the Treatment of Refractory Proliferative Arachnoiditis in CNS Tuberculosis
NCT05383742PHASE2RECRUITINGTrial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide Versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents With Tuberculous Meningitis
NCT05590455PHASE2RECRUITINGTnf Inhibitors to Reduce Mortality in HIV-1 Infected PAtients With Tuberculosis meNIngitis
NCT07227779PHASE2NOT_YET_RECRUITINGB-PaLMZ for TB Meningitis
NCT01158755PHASE2COMPLETEDIntensified Treatment Regimens for TB Meningitis: PK, PD and Tolerability Study
NCT01802502PHASE2COMPLETEDRifampicin Explorative PK Study for Tuberculous Meningitis Comparing Oral and Intravenous Preparation
NCT02237365PHASE2COMPLETEDA Pilot Study of Adjunctive Aspirin for the Treatment of HIV Negative Adults With Tuberculous Meningitis
NCT00433719Not specifiedUNKNOWNImmediate Versus Deferred Antiretroviral Therapy for HIV-Associated Tuberculous Meningitis
NCT01371916Not specifiedCOMPLETEDDiagnosis of Tuberculous Meningitis by ESAT-6 in CSF
NCT03226379Not specifiedCOMPLETEDDriving Reduced AIDS-associated Meningo-encephalitis Mortality
NCT03787940Not specifiedUNKNOWNOptimizing Antituberculosis Therapy in Adults With Tuberculous Meningitis
NCT03898635Not specifiedUNKNOWNRetrospective Real-word Study of Linezolid for the Treatment of Tuberculous Meningitis
NCT04308928Not specifiedCOMPLETEDEvaluation of New Biomarker-based Approaches for Improving the Diagnosis of Childhood Tuberculous Meningitis
NCT05636254Not specifiedUNKNOWNDiagnostic Accuracy of Imaging Findings in TBM/Spinal Tubercular Arachnoiditis and Correlation With Outcomes
NCT05781646Not specifiedCOMPLETEDXpert MTB/RIF Assay for Diagnosis of Tuberculous Meningitis (TBM) in Maharaj Nakorn Chiang Mai Hospital
NCT06811792Not specifiedCOMPLETEDIntrathecal Therapy for Adult Tuberculous Meningitis: Impact on Clinical Outcomes

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
DEXAMETHASONE42
ISONIAZID42
MOXIFLOXACIN42
PYRAZINAMIDE42
RIFAMPIN42
DEXAMETHASONE ACETATE41
ETHAMBUTOL41
LINEZOLID41
CHEMBL6356501
ZIDOVUDINE TRIPHOSPHATE-11

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 23

This page pulls from 23 datasets indexed by BioBTree:

chembl_moleculecivic_evidenceclinical_trialsclinvardbsnpefogardgenccgwasgwas_studyhgncicd10cmmedgenmeshmimmondomondochildmondoparentncitnordorphanetsctidumls